Back to top

genomics: Archive

Ekta Bagri

3 Promising Genomics Stocks to Keep an Eye On in 2025

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

BEAMNegative Net Change NTLANegative Net Change KRYSNegative Net Change MGTXNegative Net Change

Sundeep Ganoria

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

REGNNo Net Change VRTXNegative Net Change NTLANegative Net Change CRSPPositive Net Change

Sundeep Ganoria

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.

NVSNegative Net Change BMYNegative Net Change VRTXNegative Net Change BEAMNegative Net Change CRSPPositive Net Change